About half of all adults prescribed a statin stop taking it within a year. They forget, they dislike the side effects, or they simply tire of swallowing a pill every morning. That dropout rate is not a minor inconvenience. It translates directly into heart attacks and strokes that lowered cholesterol could have prevented. Now a twice-yearly injection has posted clinical trial results strong enough to reopen the question of how cholesterol treatment should work: inclisiran, sold as Leqvio and manufactured by Novartis, cut LDL cholesterol by roughly 50 percent over more than a year in large randomized trials, using a gene-silencing mechanism that lasts for months after a single shot.
What the trials showed
The core evidence comes from two phase 3 trials, ORION-10 and ORION-11, which together enrolled more than 3,000 patients with established atherosclerotic cardiovascular disease or familial hypercholesterolemia. All participants were already taking the highest statin dose they could tolerate. They received subcutaneous inclisiran injections on day 1, again at day 90, and then every six months. By day 510, the trials recorded placebo-adjusted LDL-C reductions of approximately 50 percent, according to results published in The New England Journal of Medicine. Critically, the cholesterol-lowering effect held steady between doses, with no sign of wearing off before the next injection.
Those results did not appear out of nowhere. An earlier dose-finding study, the ORION-1 trial published in JAMA Cardiology, tracked patients for a full year after one or two doses. That one-year follow-up confirmed durable LDL-C lowering and established the dosing schedule that advanced into the larger trials. The ORION program built its case in steps: proof of concept first, then dose optimization, then large-scale confirmation.
How inclisiran works, and why it lasts
Inclisiran belongs to a class of drugs called small interfering RNAs, or siRNAs. It is a short, double-stranded piece of synthetic RNA attached to a sugar molecule called GalNAc, which acts like a mailing label directing the drug specifically to liver cells. Once inside a hepatocyte, the drug triggers a natural cellular process called RNA interference: it finds and destroys the messenger RNA that tells the cell to produce PCSK9, a protein that normally pulls LDL receptors off the liver cell surface and breaks them down.
With less PCSK9 around, liver cells keep more LDL receptors active. More receptors mean more LDL cholesterol gets grabbed from the bloodstream and cleared. This mechanism, detailed in the drug’s official prescribing information, is what allows a single injection to suppress PCSK9 production for months rather than hours.
Inclisiran is not the first drug to target PCSK9. Two monoclonal antibody injections, evolocumab (Repatha) and alirocumab (Praluent), have been on the market since 2015 and produce similar LDL reductions. But those antibodies block PCSK9 after it has already been made, and they require injections every two to four weeks. Inclisiran stops PCSK9 production at the source, inside the cell, which is why its effect persists long enough to allow twice-yearly dosing. For patients and clinicians weighing options, that difference in injection frequency is a practical distinction, not just a biochemical one.
What the FDA approved, and what it did not
The FDA approved Leqvio for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who need additional LDL-C lowering beyond maximally tolerated statins. The key word is “additional.” The agency cleared it as an add-on therapy, not as a standalone replacement for statins.
That distinction creates a gap between the drug’s approved use and its broader appeal. Millions of adults who abandon statins because of muscle pain, forgetfulness, or frustration are not covered by the current label. Whether inclisiran eventually earns approval for that wider population will depend on future trial data, particularly evidence showing it prevents cardiovascular events, not just lowers a lab number.
The questions that remain open
The most important unanswered question is whether inclisiran actually prevents heart attacks, strokes, or cardiovascular deaths. The ORION trials measured LDL-C levels as a surrogate endpoint. Decades of statin research have established a strong, consistent relationship between lower LDL and fewer cardiac events, and regulators accepted that reasoning when granting approval. But a surrogate endpoint is not the same as proof that patients live longer or avoid the ICU. A large cardiovascular outcomes trial, ORION-4, is underway and designed to answer exactly that question. As of mid-2026, results from that study have not been published.
Real-world adherence is another unknown. The appeal of twice-yearly dosing is that it sidesteps the well-documented problem of patients quitting daily statins. But clinical trial adherence, where patients receive injections at scheduled study visits with reminders and follow-up, may not reflect what happens in a busy primary care practice. Patients still need to book appointments and show up. Insurance coverage, out-of-pocket costs, and access to prescribing clinicians all introduce friction that controlled trials do not capture.
Cost looms over the entire conversation. Generic statins can run a few dollars a month. The existing PCSK9 antibody injections carried initial list prices above $14,000 per year when they launched, though net prices have dropped significantly since then. The published ORION trial data and FDA documents reviewed here do not include inclisiran pricing or cost-effectiveness analyses tied to current U.S. market conditions. How aggressively insurers cover the drug will shape whether it reaches a broad patient population or stays confined to the highest-risk cases.
Long-term safety beyond roughly 18 months of follow-up has not been established in the published trial record. Injection-site reactions were the most commonly reported adverse events in ORION-10 and ORION-11, and no major safety signals emerged during those study periods. Whether off-target RNA interference effects or other concerns surface over years of repeated dosing is something only longer surveillance will clarify.
Where inclisiran’s evidence stands before outcomes data arrive
The ORION trial publications in The New England Journal of Medicine and JAMA Cardiology represent primary, peer-reviewed evidence with defined patient populations, specific endpoints, and transparent adverse-event reporting. Commentary in Nature Reviews Cardiology has placed those results in clinical context, noting that infrequent dosing could address the adherence failures that blunt statin benefits at the population level. That interpretive layer is valuable but distinct from the trial data itself.
The FDA approval confirms that regulators judged the benefit-risk profile strong enough for a defined, high-risk patient group. It does not confirm efficacy for broader populations or for outcomes beyond cholesterol reduction. Until ORION-4 delivers cardiovascular event data, inclisiran’s case rests on a powerful but incomplete foundation: a 50 percent LDL cut that lasts for months, delivered in a way that could solve one of cardiology’s most stubborn problems, but not yet proven to save lives on its own.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
